Royalty Pharma Plc (RPRX) — Strategic Asset Allocation Index
Royalty Pharma Plc (RPRX) has a Strategic Asset Allocation Index of 175.0% as of March 2026. Strategic assets (PP&E of $- plus long-term investments of $17.39 Billion) total $17.39 Billion, measured against net assets of $9.94 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Royalty Pharma Plc Strategic Asset Allocation Index (2000–2025)
This chart shows how Royalty Pharma Plc's Strategic Asset Allocation Index has evolved across 24 annual periods from 2000 to 2025. As of March 2026, the index stands at 175.0%, representing strategic assets of $17.39 Billion against net assets of $9.94 Billion USD. Explore Royalty Pharma Plc (RPRX) cash conversion ratio to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Royalty Pharma Plc (2000–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Royalty Pharma Plc from 2000 to 2025, covering 24 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Royalty Pharma Plc market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 175.9% | $17.09 Billion | $- | $17.09 Billion | $9.71 Billion | ▲ +17.5 pp |
| 2024 | 158.4% | $16.39 Billion | $- | $16.39 Billion | $10.34 Billion | ▲ +8.7 pp |
| 2023 | 149.7% | $15.10 Billion | $- | $15.10 Billion | $10.08 Billion | ▲ +1.5 pp |
| 2022 | 148.2% | $14.12 Billion | $- | $14.12 Billion | $9.53 Billion | ▲ +8.1 pp |
| 2021 | 140.1% | $14.36 Billion | $- | $14.36 Billion | $10.25 Billion | ▲ +53.5 pp |
| 2020 | 86.6% | $12.97 Billion | $- | $12.97 Billion | $14.97 Billion | ▼ -100.3 pp |
| 2019 | 186.9% | $11.48 Billion | $- | $11.48 Billion | $6.14 Billion | ▼ -3.5 pp |
| 2018 | 190.4% | $8.67 Billion | $- | $8.67 Billion | $4.55 Billion | ▲ +190.4 pp |
| 2016 | 0.0% | $3.00K | $3.00K | $- | $4.46 Billion | ▼ 0.0 pp |
| 2015 | 0.0% | $8.00K | $8.00K | $- | $4.70 Billion | ▼ -0.1 pp |
| 2014 | 0.1% | $32.00K | $32.00K | $- | $44.02 Million | ▼ 0.0 pp |
| 2013 | 0.1% | $75.00K | $75.00K | $- | $75.42 Million | ▼ -0.1 pp |
| 2012 | 0.2% | $53.00K | $53.00K | $- | $23.03 Million | ▼ -0.1 pp |
| 2011 | 0.3% | $15.00K | $15.00K | $- | $4.67 Million | ▲ +0.1 pp |
| 2010 | 0.2% | $7.00K | $7.00K | $- | $3.17 Million | ▼ -1.9 pp |
| 2009 | 2.1% | $12.00K | $12.00K | $- | $562.00K | ▲ +2.0 pp |
| 2008 | 0.2% | $28.00K | $28.00K | $- | $15.61 Million | ▼ 0.0 pp |
| 2007 | 0.2% | $47.00K | $47.00K | $- | $24.06 Million | ▼ -1.5 pp |
| 2006 | 1.7% | $65.00K | $65.00K | $- | $3.79 Million | ▲ +1.6 pp |
| 2005 | 0.1% | $19.00K | $19.00K | $- | $16.95 Million | ▼ -0.2 pp |
| 2004 | 0.3% | $18.00K | $18.00K | $- | $5.99 Million | ▼ -0.4 pp |
| 2002 | 0.7% | $191.00K | $191.00K | $- | $26.85 Million | ▼ -0.4 pp |
| 2001 | 1.1% | $340.00K | $340.00K | $- | $30.57 Million | ▼ -0.7 pp |
| 2000 | 1.8% | $556.00K | $556.00K | $- | $31.06 Million | — |